Pralsetinib治疗晚期或转移性RET变异甲状腺癌:ARROW多队列开放标签1/2期注册研究
ARROW研究评估了选择性RET抑制剂pralsetinib在RET变异甲状腺癌患者中的安全性和抗肿瘤活性,纳入122例RET突变型甲状腺髓样癌和20例RET融合阳性甲状腺癌患者。在可测量病灶患者中,初治RET突变型甲状腺髓样癌客观缓解率为71%(95%CI 48-89),既往接受卡博替尼或凡德他尼治疗者为60%(95%CI 46-73),RET融合阳性甲状腺癌为89%(95%CI 52-100)。常见≥3级治疗相关不良事件包括高血压17%、中性粒细胞减少13%、淋巴细胞减少12%和贫血10%。
要点
- Pralsetinib在RET变异甲状腺癌中显示高客观缓解率,RET融合阳性者达89%。
- 初治和经治RET突变型甲状腺髓样癌客观缓解率分别为71%和60%。
- 常见≥3级不良事件为高血压、中性粒细胞减少、淋巴细胞减少和贫血。
核心结论
- Pralsetinib是一种耐受性良好、强效的每日一次口服治疗选择,适用于RET变异甲状腺癌患者。
研究设计与样本
- ARROW为1/2期、开放标签研究,在13个国家71个中心纳入18岁及以上RET变异局部晚期或转移性实体瘤患者。
- 患者每日口服pralsetinib 400 mg直至疾病进展、不耐受、撤回知情同意或研究者决定。
- 疗效分析纳入截至2019年7月11日接受治疗且有基线可测量病灶的患者;安全性分析纳入截至2020年5月22日入组的RET变异甲状腺癌患者。
主要发现
- 初治RET突变型甲状腺髓样癌客观缓解率为71%(15/21,95%CI 48-89)。
- 既往接受卡博替尼或凡德他尼或两者治疗的RET突变型甲状腺髓样癌客观缓解率为60%(33/55,95%CI 46-73)。
- RET融合阳性甲状腺癌客观缓解率为89%(8/9,95%CI 52-100)。
- 常见(≥10%)≥3级治疗相关不良事件:高血压24例(17%)、中性粒细胞减少19例(13%)、淋巴细胞减少17例(12%)、贫血14例(10%)。
- 严重治疗相关不良事件21例(15%),最常见为肺炎5例(4%);5例(4%)因治疗相关事件停药,1例(1%)因治疗相关不良事件死亡。
关键数值与推荐
- 客观缓解率采用RECIST 1.1标准,由盲法独立中心审查评估。
- RET突变型甲状腺髓样癌患者需既往接受卡博替尼或凡德他尼或两者,或不适合标准治疗。
- RET融合阳性甲状腺癌患者需既往接受过治疗。
临床怎么用
- 对于RET变异甲状腺癌患者,pralsetinib 400 mg每日一次口服可作为新的靶向治疗选择。
- 治疗期间需监测高血压、中性粒细胞减少、淋巴细胞减少、贫血和肺炎等不良事件。
局限性
- RET融合阳性甲状腺癌队列样本量小(9例可评估疗效),且入组仍在进行中。
- 本研究为开放标签单臂设计,无对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oncogenic alterations in RET represent important therapeutic targets in thyroid cancer. We aimed to assess the safety and antitumour activity of pralsetinib, a highly potent, selective RET inhibitor, in patients with RET-altered thyroid cancers. METHODS: ARROW, a phase 1/2, open-label study done in 13 countries across 71 sites in community and hospital settings, enrolled patients 18 years or older with RET-altered locally advanced or metastatic solid tumours, including RET-mutant medullary thyroid and RET fusion-positive thyroid cancers, and an Eastern Co-operative Oncology Group performance status of 0-2 (later limited to 0-1 in a protocol amendment). Phase 2 primary endpoints assessed for patients who received 400 mg once-daily oral pralsetinib until disease progression, intolerance, withdrawal of consent, or investigator decision, were overall response rate (Response Evaluation Criteria in Solid Tumours version 1.1; masked independent central review) and safety. Tumour response was assessed for patients with RET-mutant medullary thyroid cancer who had received previous cabozantinib or vandetanib, or both, or were ineligible for standard therapy and patients with previously treated RET fusion-positive thyroid cancer; safety was assessed for all patients with RET-altered thyroid cancer. This ongoing study is registered with clinicaltrials.gov, NCT03037385, and enrolment of patients with RET fusion-positive thyroid cancer was ongoing at the time of this interim analysis. FINDINGS: Between Mar 17, 2017, and May 22, 2020, 122 patients with RET-mutant medullary and 20 with RET fusion-positive thyroid cancers were enrolled. Among patients with baseline measurable disease who received pralsetinib by July 11, 2019 (enrolment cutoff for efficacy analysis), overall response rates were 15 (71%) of 21 (95% CI 48-89) in patients with treatment-naive RET-mutant medullary thyroid cancer and 33 (60%) of 55 (95% CI 46-73) in patients who had previously received cabozantinib or vandetanib, or both, and eight (89%) of nine (95% CI 52-100) in patients with RET fusion-positive thyroid cancer (all responses confirmed for each group). Common (≥10%) grade 3 and above treatment-related adverse events among patients with RET-altered thyroid cancer enrolled by May 22, 2020, were hypertension (24 patients [17%] of 142), neutropenia (19 [13%]), lymphopenia (17 [12%]), and anaemia (14 [10%]). Serious treatment-related adverse events were reported in 21 patients (15%), the most frequent (≥2%) of which was pneumonitis (five patients [4%]). Five patients [4%] discontinued owing to treatment-related events. One (1%) patient died owing to a treatment-related adverse event. INTERPRETATION: Pralsetinib is a new, well-tolerated, potent once-daily oral treatment option for patients with RET-altered thyroid cancer. FUNDING: Blueprint Medicines.
引用
- Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021. PMID: 34118198. doi:10.1016/S2213-8587(21)00120-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。